Clinical Breast Cancer

Official account of CBC, a journal publishing 8 issues/year on various aspects of clinical & translational breast cancer research. IF 3.225 | RTs ≠ endorsement.

[Hao Yin @HaoYin20]

#MetaplasticBreastCancer

Spindle cell/Sarcomatous histologic type N=36 is associated with reduced 3-/5-yr Recurrence-free survival & Overall survival
vs other histologic types N=70

In this cohort, MpBC N=106 vs non-Mp TNBC N=106 have similar survival

Discussion contains an important summary of previous studies on MpBC prognosis.

@CBCjournal 2025
https://t.co/xvkD9gQ3at

[Clinical Breast Cancer @CBCjournal]

Systematic review of nonpharmacological interventions for postmastectomy pain syndrome (PMPS).

🔹 Fat grafting & lymph node transplantation → ⬆️QoL & ⬇️pain
🔹 Pulsed radiofrequency
🔹 TENS & dry needling → most effective PT approaches

#bcsm
https://t.co/EaK57VhUuL

[Clinical Breast Cancer @CBCjournal]

Real-World Analysis of BC pts Qualifying for Adjuvant CDK4/6i (n=3,840)
🔹 17.5% met abemaciclib eligibility
🔹 41.3% met ribociclib eligibility
🔹 Eligible pts had lower stage/nodal burden vs phase III trials
#bcsm
https://t.co/kdYt4uBvAs

[Clinical Breast Cancer @CBCjournal]

In HER2 positive #DCIS treated with BCS + RT, a 7-gene biosignature (DCISionRT) with Residual Risk subtype (RRt) identified patients at significantly higher 10-yr in-breast recurrence risk (16.2% vs 1.6%).

#bcsm
https://t.co/xSpSb9sDb5

[Clinical Breast Cancer @CBCjournal]

Progesterone receptor (PR) expression in #BreastCancer is more than a biomarker.

🔹 Analysis of 2,223 pts (IPO-Porto)
🔹 PR status linked to BMI, histology, grade, stage, ER & HER2
🔹 PR– tumors associated with advanced stage & worse OS
#bcsm
https://t.co/pw3eavkJ7R

[Clinical Breast Cancer @CBCjournal]

Is breast-conserving therapy (BCT) safe for multifocal/multicentric breast cancer (MF/MCBC)?

🔹Meta-analysis (28,589 pts)
🔹 MF/MCBC had higher LR vs unifocal disease
🔹 LR rates comparable btw BCT & mastectomy
🔹 DFS & OS outcomes favorable
#bcsm
https://t.co/cSvnBpSbI2

[Seamus O’Reilly MD PhD @Seamusoreilly18]

Solution 🌳of Sustainability for Breast Cancer Care 👇

Grateful to ✍️ co- authors for their insights

[Clinical Breast Cancer @CBCjournal]

Climate change is the greatest threat to human health—and it directly impacts BC care.

This review maps intersections between breast cancer care & planetary health and proposes a solution tree for sustainable, low-carbon practice. #bcsm
@Seamusoreilly18

https://t.co/LxOrKcsddC

[Clinical Breast Cancer @CBCjournal]

Black women face higher breast cancer mortality despite similar incidence to White women.

🧬 Universal genetic counseling/testing could aid earlier risk identification
⚡ Higher TNBC rates & earlier onset already meet NCCN criteria
#bcsm @sofiamerajver
https://t.co/jwiEQ6Ll95

[Clinical Breast Cancer @CBCjournal]

💡 In HER2+ breast cancer patients who achieve pCR after neoadjuvant chemo + trastuzumab/pertuzumab (TP), adjuvant therapy choice may not impact outcomes.

👉 3-yr RFS: 94.2% (TP) vs 95.6% (T)
👉 No differences in brain mets or survival
#bcsm #CBCjournal
https://t.co/OANpokwcDV

[IU Simon Comprehensive Cancer Center @IUCancerCenter]

A new article was published in Clinical Breast Cancer by the cancer center’s Tarah Ballinger, MD, and colleagues. Learn more: https://t.co/sLF0rwr716. #ResearchCuresCancer #NCIcomprehensive @CBCjournal

[Clinical Breast Cancer @CBCjournal]

New meta-analysis: Tranexamic acid (TXA) significantly reduces postoperative hematoma after breast surgery.

🔹 Both topical & IV TXA cut hematoma risk
🔹 Less drain output & earlier drain removal
🔹 No increase in infection or thromboembolic events
#bcsm

https://t.co/WmAD6wXIAf

[Clinical Breast Cancer @CBCjournal]

PreciseDx Breast is a digital risk assessment test that predicts early BC recurrence within 6-years of diagnosis. Read more👇
#bcsm @IcahnMountSinai
https://t.co/2fYW9kgAbu

[Clinical Breast Cancer @CBCjournal]

Radiation omission in pts w/ early BC is a dynamically changing paradigm. Individualizing treatment is paramount and understanding an individual pt's goals of treatments and values is key. Read more 👇

#bcsm
@RoswellPark @si_fkf @MFarrugiaXRT @CShahMD

https://t.co/ZFPoOYjua4

[Clinical Breast Cancer @CBCjournal]

A study evaluating forequarter amputation (FA) in BC (locally advanced/recurrent tumor, Stewart & Treves syndrome, radiation-induced sarcoma) showed that FA has few complications & attenuates symptoms in pts tx with both curative & palliative intent.

https://t.co/iDehbg3ljC

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

🔔Hot off the press! Optimizing Postneoadjuvant Treatment of Residual #BreastCancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy
🔓Free access until 03/21: https://t.co/nF0T1vqxTh
✍️@CBCjournal @darioT_ @JinQingchun @hoperugo
@YAbdouMD @CARLAISADORA @NabihahTayob
@stolaney1 @DrHBurstein @elmayermd

[Clinical Breast Cancer @CBCjournal]

A Clinical Review on Antibody-Drug Conjugates in TNBC, summarizing Current Data and Future Developments.

@kilicmerwe @WinshipAtEmory
https://t.co/ulFcmxfVWs

[Liang Cheng, MD @LiangChengMD]

Just published in the February 2025 issue of Clinical Breast Cancer @CBCjournal
Congratulations to Professor Yihong Wang and colleagues @BrownMedicine @BrownUCancer @BrownPathology
    In our study of 224 node-positive breast cancer patients treated with neoadjuvant chemotherapy, we found that axillary and locoregional recurrences were rare (3.4%) in a selected group of yN0 patients who underwent SLNB and/or ALND. Additionally, SLNB with fewer than two positive nodes rarely resulted in a significantly different yield of positive non-SLNs or impacted short-term oncologic outcomes compared to ALND. These findings suggest that de-escalation of axillary surgery to SLNB alone may be a safe option in this patient population.
Full article available at the following link
https://t.co/XNUtpei4jB

[Clinical Breast Cancer @CBCjournal]

A Clinical Review of the Role of Immunotherapy in TNBC, with an Overview of Data from Seminal Trials for both Early and Advanced TNBC.

#bcsm
@RitaNandaMD @UChicagoMed

https://t.co/rWf16YatFV

[Clinical Breast Cancer @CBCjournal]

NH Black women have ⬆️ risk of TNBC yet, they are less likely to undergo genetic counseling / testing and less likely to receive guideline-directed screening and risk-reduction compared to NH White women.
#bcsm #disparities
@dsmithgraz @WinshipAtEmory
https://t.co/9nnkWoeyTI